EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antisense oligonucleotides modulate aberrant inclusion of poison exons in SCN1A-related Dravet syndrome

Sheng Tang, Hannah Stamberger, Jeffrey D Calhoun, Sarah Weckhuysen, Gemma L Carvill

JCI Insight · 2025

DOI: 10.1172/jci.insight.188014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, 2025. Verfasst von Sheng Tang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: NAV1.1 Voltage-Gated Sodium Channel, Epilepsies, Myoclonic, Oligonucleotides, Antisense, Exons. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NICHD NIH HHS, NINDS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dravet syndrome is a developmental and epileptic encephalopathy associated with pathogenic variants in SCN1A. Most disease-causing variants are located within coding regions, but recent work has shed light on the role of noncoding variants associated with a poison exon in intron 20 of SCN1A. Discovery of the SCN1A poison exon known as 20N has led to the first potential disease-modifying therapy for Dravet syndrome in the form of an antisense oligonucleotide. Here, we demonstrate the existence of 2 additional poison exons in introns 1 and 22 of SCN1A through targeted, deep-coverage long-read sequencing of SCN1A transcripts. We show that inclusion of these poison exons is developmentally regulated in the human brain, and that deep intronic variants associated with these poison exons lead to their aberrant inclusion in vitro in a minigene assay or in iPSC-derived neurons. Additionally, we show that splice-modulating antisense oligonucleotides can ameliorate aberrant inclusion of poison exons. Our findings highlight the role of deep intronic pathogenic variants in disease and provide additional therapeutic targets for precision medicine in Dravet syndrome and other SCN1A-related disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NAV1.1 Voltage-Gated Sodium ChannelEpilepsies, MyoclonicOligonucleotides, AntisenseExonsHumansIntronsNeuronsBrain

Stichwörter der Autor:innen

EpilepsyGene therapyGeneticsNeuroscience

Substanzen

NAV1.1 Voltage-Gated Sodium ChannelOligonucleotides, AntisenseSCN1A protein, human

Autor:innen und Institutionen

  • Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Applied & Translational Neurogenomics Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
  • Translational Neurosciences, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium.
  • Department of Neurology, Antwerp University Hospital, Antwerp, Belgium.

Förderung

  • NINDS NIH HHS
  • NICHD NIH HHS
  • NINDS
  • NICHD

Zitieren

APA

Tang, S., Stamberger, H., Calhoun, J. D., Weckhuysen, S., & Carvill, G. L. (2025). Antisense oligonucleotides modulate aberrant inclusion of poison exons in SCN1A-related Dravet syndrome. JCI Insight. https://doi.org/10.1172/jci.insight.188014

Vancouver

Tang S, Stamberger H, Calhoun JD, Weckhuysen S, Carvill GL. Antisense oligonucleotides modulate aberrant inclusion of poison exons in SCN1A-related Dravet syndrome. JCI Insight. 2025. doi:10.1172/jci.insight.188014

BibTeX
@article{Tang2025,
  author = {Tang, Sheng and Stamberger, Hannah and Calhoun, Jeffrey D and Weckhuysen, Sarah and Carvill, Gemma L},
  title = {Antisense oligonucleotides modulate aberrant inclusion of poison exons in SCN1A-related Dravet syndrome},
  journal = {JCI Insight},
  year = {2025},
  doi = {10.1172/jci.insight.188014}
}
Kostenlos starten →